GlassScriptPhysician profile
Ann M Weber
NPI 1073932026
$9,317.10
in general payments reported to CMS, 2019-2025
27 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,196 · 2022: $1,577 · 2023: $1,895 · 2024: $2,010 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,429 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,428.75 |
| Education | $115.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.68 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,124.76 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,068.14 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $745.59 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $726.56 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $664.62 | 2022-2025 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $565.06 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $474.36 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $382.38 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Indivior INC. | $340.28 | 2022-2025 | Sublocade, Perseris |
| Corium, LLC | $337.57 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $312.01 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $256.67 | 2023-2025 | Auvelity |
| Tris Pharma INC | $212.39 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $137.30 | 2023-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $136.43 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $121.00 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $117.14 | 2023-2025 | Secuado |
| Braeburn INC. | $106.50 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $81.36 | 2024-2025 | Hetlioz, Fanapt |
| Microtransponder, INC. | $61.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.28 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $57.49 | 2025 | Loreev Xr |
| Luye Pharma (USA) LTD. | $29.27 | 2025 | Erzofri Extended-Release |
| Neuronetics, INC. | $27.71 | 2023 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $18.58 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.